Enzalutamide KOL Commentaries - Enzalutamide KOL Commentary Primary and novel androgen deprivation therapy for prostate cancer: balancing efficacy and potential toxicitiesMary-Ellen Taplin VIEW MORE Case study Case Study (2019-2023): Changing treatmentsMary-Ellen Taplin VIEW MORE KOL Commentary Novel therapeutic strategies that are helping HCPs manage patients and improving outcomesWilliam Oh VIEW MORE Infographics - Enzalutamide Biomarkers for the Prediction of Disease Progression, Prognosis, and Treatment Response of Metastatic Prostate Cancer VIEW INFOGRAPHIC Intensifying Metastatic Hormone-Sensitive Prostate Cancer Treatment VIEW INFOGRAPHIC Articles - Enzalutamide The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups READ MORE Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins READ MORE Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer READ MORE Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk READ MORE Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol READ MORE Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer READ MORE Facebook Twitter Linkedin
